Media stories about Integra Lifesciences (NASDAQ:IART) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Integra Lifesciences earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the life sciences company an impact score of 46.2398552045215 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Contrasting Integra Lifesciences (IART) & T2 Biosystems (TTOO) (americanbankingnews.com)
- Integra Lifesciences Holdings Corp Forecasted to Post FY2017 Earnings of $1.84 Per Share (IART) (americanbankingnews.com)
- Integra Lifesciences’ (IART) “Hold” Rating Reiterated at Barclays (americanbankingnews.com)
- Integra Lifesciences Holdings Corp (IART) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Integra LifeSciences Sees Q4 Revenue Above View (markets.businessinsider.com)
Shares of Integra Lifesciences (NASDAQ IART) traded up $0.10 on Friday, reaching $50.57. 352,799 shares of the company’s stock were exchanged, compared to its average volume of 505,972. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $3,960.76, a PE ratio of 82.90, a P/E/G ratio of 1.68 and a beta of 0.65. Integra Lifesciences has a twelve month low of $40.51 and a twelve month high of $56.42.
IART has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Royal Bank of Canada reiterated a “sector perform” rating and set a $50.00 price target (up from $48.00) on shares of Integra Lifesciences in a report on Thursday, November 9th. Oppenheimer set a $58.00 price target on shares of Integra Lifesciences and gave the stock a “buy” rating in a report on Tuesday, December 12th. Wells Fargo & Co cut shares of Integra Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Sunday, October 29th. Finally, JPMorgan Chase & Co. cut shares of Integra Lifesciences from an “overweight” rating to a “neutral” rating and set a $44.00 price objective on the stock. in a research note on Friday, October 27th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $52.70.
In other news, Director Barbara B. Hill purchased 10,768 shares of the business’s stock in a transaction on Tuesday, October 31st. The shares were acquired at an average price of $46.66 per share, with a total value of $502,434.88. Following the completion of the transaction, the director now owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the sale, the vice president now directly owns 21,665 shares in the company, valued at approximately $1,022,371.35. The disclosure for this sale can be found here. Corporate insiders own 21.50% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with our FREE daily email newsletter.